Open Label Extension Study of Bifeprunox

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: All

Summary

A one year extension study using flexible doses, 20 or 30 mg daily, of open-label bifeprunox.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Criteria

Inclusion Criteria:

1. Outpatients who have successfully completed Wyeth study 3168A1-311-US.

2. A signed and dated informed consent form for this study.

3. No major protocol violations in previous study.

Exclusion Criteria:

1. Clinically important abnormalities noted in preceding short-term study that have not resolved.

2. Use of prohibited treatments in the preceding short-term study.

3. Meeting any exclusion criteria for the preceding short-term study.